Dual MAPK inhibition (dMAPKi) as an effective therapeutic strategy for class II BRAF mutant (mt) metastatic melanoma (MM).
Matthew Dankner(McGill University), April A. N. Rose(Jewish General Hospital), Dana Vuzman, Dan Moldoveanu(McGill University Health Centre), Kevin Petrecca(McGill University Health Centre), Mathieu Lajoie(McGill University Health Centre), Xiu Huang(Nickel Institute), Paul Savage(Unknown), Ian R. Watson(McGill University), Shivshankari Rajkumar(McGill University Health Centre), Catalin Mihalcioiu(McGill University Health Centre), David Hogg(University of Leeds), Tan Trieu Nguyen(McGill University), Peter M. Siegel(L'Oréal (France)), Anna Spreafico(University Health Network), Morag Park(McGill University Health Centre), Maria Lvova(Nickel Institute), Alexei Protopopov, Marie‐Christine Guiot(McGill University), Marcus O. Butler(University of Toronto)
Cited by 0
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study
|The Lancet Oncology|2014|978
Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma
|New England Journal of Medicine|2021|869
A Pan-Cancer Proteogenomic Atlas of PI3K/AKT/mTOR Pathway Alterations
|Cancer Cell|2017|656